Table 1.
Clinical and Treatment Characteristics Before and After Chimeric Antigen Receptor T-Cell Therapy.
| ALL, n = 55 | NHL, n = 34 | P | Total, n = 89 | |
|---|---|---|---|---|
| Baseline characteristics | ||||
| Age, median (range), years | 27 (7–67) | 48 (23–71) | <0.001 | 35 (7–71) |
| Female | 28 (50.9%) | 13 (38.2%) | 0.246 | 41 (46.1%) |
| Prior antitumor treatment regimens | 5 (2–24) | 8 (5–24) | <0.001 | 6 (2–24) |
| IgG, median (range), mg/dL | 745 (302–1,856) | 700 (195–1,321) | 0.430 | 744 (195–1,856) |
| ANC < 500 cells/mm3 before CTI | 15 (27.3%) | 2 (5.9%) | 0.013 | 17 (19.1%) |
| Fever before CTI | 24 (43.6%) | 7 (20.6%) | 0.027 | 31 (34.8%) |
| Prior autologous and/or allogeneic HSCT | 17 (30.9%) | 4 (11.8%) | 0.040 | 21 (23.6%) |
| Infection in prior treatment | 15 (27.3%) | 5 (14.7%) | 0.170 | 20 (22.5%) |
| Disease status | ||||
| ≤20% blastsa/I–IIb | 20 (36.4%) | 9 (26.5%) | 0.362 | 29 (32.6%) |
| >20% blastsa/III–IVb | 35 (63.6%) | 25 (73.5%) | 60 (67.4%) | |
| Post CAR-T cell characteristics | ||||
| Duration of neutropenia | 6 (0–78) | 1.5 (1–36) | <0.001 | 4 (0–78) |
| Duration of fever | 7 (0–45) | 6 (0–63) | 0.091 | 6 (0–63) |
| CRS gradec | ||||
| 0 | 7 (12.7%) | 5 (14.7%) | 0.001 | 12 (13.5%) |
| 1–2 | 29 (52.7%) | 23 (67.6%) | 52 (58.4%) | |
| 3–5 | 19 (34.7%) | 6 (17.6%) | 25 (28.1%) | |
| Corticosteroid | 6 (10.9%) | 5 (14.7%) | 0.599 | 11 (12.4%)d |
| Tocilizumab | 18 (32.7%) | 5 (14.7%) | 0.061 | 23 (25.8%)d |
| Length of stay, median (range), days | 33 (14–103) | 18 (11–104) | <0.001 | 27 (11–104) |
ALL: acute lymphoblastic leukemia; ANC: absolute neutrophil count; CAR-T: chimeric antigen receptor T cell; CICAE: common terminology criteria for adverse events; CRS: cytokine release syndrome; CTI: CAR-T cell infusion; HSCT: hematopoietic stem cell transplantation; IgG: immunoglobulin G; NHL: non-Hodgkin’s lymphoma.
aBlasts referred to the blast cells in the bone marrow.
b Patients with NHL were examined via positron emission tomographic/computed tomographic scanning before CTI and staged in accordance with the results.
c The severity of CRS was graded according to 4.0.
d Fourteen patients received only tocilizumab, two patients received only corticosteroids, and nine patients received both.